Bio & Pharma
Celltrion establishes subsidiary in Vietnam
The company plans to obtain local sales approval for Remsima, Remsima SC, Truxima, and Herzuma in 2024
By Sep 30, 2024 (Gmt+09:00)
1
Min read
Most Read
MBK wins enough stake in tender offer to control Korea Zinc
Flashlight Capital offers to buy KT&G’s ginseng business for $1.4 billion
Corporate management disputes spring up in S.Korea
MBK not to raise Korea Zinc tender offer price after regulator warning
Korea Zinc ups share buyback price, volume to counter MBK
Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam.
Celltrion plans to obtain approval to sell its major products, including Remsima, Remsima SC, Truxima, and Herzuma this year and supply these treatments across Vietnam.
Celltrion stated that it plans to expand its local workforce by more than double digits by the end of the year, hiring professionals for pharmaceutical sales and marketing.
The company will also build a communication network with Vietnam’s bidding agencies.
"Vietnam is a key pharmaceutical market within the ASEAN region, with an annual market size estimated at around 10 trillion won ($7.7 billion)," a Celltrion source added.
The company plans to complete product registration in major hospitals capable of prescribing biopharmaceuticals by the first half of next year.
Write to Jeong Min Nam at peux@hankyung.com
Celltrion plans to obtain approval to sell its major products, including Remsima, Remsima SC, Truxima, and Herzuma this year and supply these treatments across Vietnam.
Celltrion stated that it plans to expand its local workforce by more than double digits by the end of the year, hiring professionals for pharmaceutical sales and marketing.
The company will also build a communication network with Vietnam’s bidding agencies.
"Vietnam is a key pharmaceutical market within the ASEAN region, with an annual market size estimated at around 10 trillion won ($7.7 billion)," a Celltrion source added.
The company plans to complete product registration in major hospitals capable of prescribing biopharmaceuticals by the first half of next year.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Bio & PharmaCelltrion to supply breast, stomach cancer treatment to Brazil
Sep 13, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion earmarks billions of dollars to build CDMO plant: chairman
Sep 11, 2024 (Gmt+09:00)
2 Min read -
Bio & PharmaCelltrion chairman announces venture into CDMO market
Sep 09, 2024 (Gmt+09:00)
2 Min read
Comment 0
LOG IN